Jump to section
IdentificationPharmacologyInteractionsReferencesTrialsEconomicsPropertiesSpectraTaxonomyIdentification
- Name
- Ubidecarenone
- Accession Number
- DB09270
- Type
- Small Molecule
- Groups
- Approved, Investigational, Nutraceutical
- Description
Ubidecarenone, also known as coenzyme Q10, is a 1,4-benzoquinone, where Q refers to the quinone chemical group, and 10 refers to the number of isoprenyl chemical subunits in its tail.[1] It is a powerful antioxidant, a lipid-soluble and essential cofactor in mitochondrial oxidative phosphorylation.[2] The ubidecarenone is the coenzyme destined for mitochondrial enzyme complexes involved in oxidative phosphorylation in the production of ATP. It is fundamental for cells that have a high metabolic demand.[7] Ubidecarenone is sold as a dietary supplement and is not FDA approved as a drug thus, it is not meant to treat, cure or prevent any disease. FDA does not approve this dietary supplements before sold nor regulate the manufacturing process.[8]
- Structure
Structure for DB09270 (Ubidecarenone)
- Synonyms
- Coenzyme Q-10
- Coenzyme Q10
- External IDs
- API 31510 / API-31510 / NSC-140865
- Product Ingredients
Ingredient UNII CAS InChI Key Coenzyme q10, (2z)- U705VLF0VW 65085-29-2 ACTIUHUUMQJHFO-LLOLQPSSSA-N - Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Co-enzyme Q-10 Capsules Capsule 30 mg Oral Ashbury Research Corporation Not applicable Not applicable Canada 
Co-q10 (ubiquinone) Capsule 60 mg Oral Abundance Naturally Ltd Not applicable Not applicable Canada Q-gel Coenzyme Q10 Capsule 15 mg Oral T & T Nutrition Inc. Not applicable Not applicable Canada Watkins Coq10 Tablet 60 mg Oral Watkins Incorporated Not applicable Not applicable Canada - Over the Counter Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Acti-ubiquinone 50 Cap 50mg Capsule 50 mg Oral Acti Form Ltd. 1991-12-31 2005-03-21 Canada Biogard Ubiquinone Cap 30mg Capsule 30 mg Oral Sisu Inc. 1994-12-31 2001-08-01 Canada Biomed Co Q 10 Capsule 100 mg Oral Sisu Inc. 1998-02-11 2008-07-25 Canada Cell Tech Coenzyme Q10 - Cap 30mg Capsule 30 mg Oral Cell Tech 1996-11-12 2000-10-05 Canada Cellsparc 360 Capsule 60 mg Oral Aim International, Inc. 1998-07-29 2008-09-03 Canada Co Q 10 - 50mg Cap Capsule 50 mg Oral Albi Naturals 1994-12-31 2008-07-17 Canada Co-enzyme Q-10 Capsule 30 mg Oral Holista Health (Canada) Inc. 1996-12-31 2002-08-06 Canada Co-enzyme Q-10 Capsule 30 mg Oral Seroyal International Inc. 1995-12-31 2008-07-14 Canada Co-enzyme Q10 100mg Capsule 100 mg Oral Natural Factors Nutritional Products Ltd. 1999-07-12 2009-09-28 Canada Co-enzyme Q10 30mg Capsules Capsule 30 mg Oral Alive Vitamins 1998-07-27 2005-07-04 Canada - Mixture Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Biosculpt Ubidecarenone (1.5 mg) + Choline bitartrate (0.3 mg) + Chromium (40 mcg) + Calcium pantothenate (60 mg) + Pyridoxine hydrochloride (4 mg) + myo-inositol (0.3 mg) Solution Oral Maxion Nutrition Corp. 2002-06-10 2004-07-20 Canada Co-q10 and Vitamin E Ubidecarenone (100 mg) + Vitamin E (300 unit) Capsule Oral Biomed International Products Corp. 2003-10-01 2006-06-29 Canada Coen.q10w.vit.c and E Beta-car.se Cu Zn Mn Ubidecarenone (10 mg) + Beta carotene (5000 unit) + Copper (1 mg) + D-alpha-Tocopherol acetate (200 unit) + Manganese (5 mg) + Selenium (15 mcg) + Vitamin C (300 mg) + Zinc (5 mg) Capsule Oral Jamieson Laboratories Ltd 1995-12-31 2001-09-14 Canada Coenzyme Q10 + Ubidecarenone (30 mg) + Vitamin E (30 mg) Capsule Oral Body Wise International Llc Not applicable Not applicable Canada Coenzyme Q10 Isotonix Vitamin and Mineral Supplement Ubidecarenone (30.03 mg) + Potassium (32.43 mg) + Riboflavin (0.9 mg) + Vitamin E (60.06 mg) Powder Oral Market America 2002-06-04 2008-09-04 Canada Daily Supplement Packs Ubidecarenone (30 mg) + Cyanocobalamin (125 mcg) + Folic Acid (0.4 mg) + Magnesium (150 mg) + Pyridoxine (50 mg) + Vitamin E (400 unit) Capsule Oral Wn Pharmaceuticals Ltd. 2002-10-18 2005-08-15 Canada Formula B Ubidecarenone (30 mg) + Magnesium (200 mg) + Pyridoxine (25 mg) + Thiamine (25 mg) + Vitamin C (250 mg) + Zinc (30 mg) Capsule Oral Balance Plus, Inc. 2000-04-19 2004-08-17 Canada Formula Cp Cap Ubidecarenone (1 mg) + Beta carotene (2500 unit) + Cyanocobalamin (2 mcg) + D-alpha-Tocopherol acetate (26 unit) + Folic Acid (.04 mg) + Magnesium (31.5 mg) + Niacin (.55 mg) + Nicotinamide (3.55 mg) + Potassium (20 mg) + Selenium (11.5 mcg) + Vitamin C (90 mg) + Zinc (2 mg) Capsule Oral Enrich International 1994-12-31 2002-08-09 Canada Formula Dpr Ubidecarenone (30 mg) + Riboflavin (30 mg) Capsule Oral Balance Plus, Inc. 2000-03-08 2004-08-17 Canada Formula Statin Support Ubidecarenone (30 mg) + Cyanocobalamin (50 mcg) + Magnesium (200 mg) + Pantothenic acid (50 mg) + Pyridoxine (50 mg) Capsule Oral Balance Plus, Inc. 2000-04-19 2004-08-17 Canada - Unapproved/Other Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Lexazin Coenzyme q10, (2z)- (50 mg/1) + Cholecalciferol (500 [iU]/1) + Folic Acid (1 mg/1) + Methylcobalamin (5 mg/1) + NADH (5 mg/1) + Pyridoxal Phosphate (12.5 mg/1) + Thiamine hydrochloride (25 mg/1) + Vitamin C (125 mg/1) Capsule Oral Sterling Knight Pharmaceuticals, Llc 2018-01-02 Not applicable US 
PreQue 10 Ubidecarenone (50 mg/1) + Cholecalciferol (120 [iU]/1) + Cupric oxide (1 mg/1) + Cyanocobalamin (1 ug/1) + Doconexent (50 mg/1) + Docusate sodium (25 mg/1) + Folic Acid (.5 mg/1) + Iron (15 mg/1) + Lycopene (5 mg/1) + Magnesium oxide (10 mg/1) + Riboflavin (1.7 mg/1) + Selenium (7.5 ug/1) + Thiamine (1 mg/1) + Vitamin A (1250 [iU]/1) + Vitamin C (30 mg/1) + Vitamin E (15 [iU]/1) + Zinc oxide (12.5 mg/1) Tablet Oral Actavis Pharma Company 2011-11-01 Not applicable US Vita-Rx Diabetic Vitamin Ubidecarenone (50 mg/1) + Biotin (2.5 mg/1) + Cholecalciferol (.0625 mg/1) + Chromium picolinate (.465 mg/1) + D-alpha-Tocopherol acetate (10 mg/1) + Folic Acid (.8 mg/1) + Lipoic Acid (150 mg/1) + Methylcobalamin (.0025 mg/1) + Niacin (20 mg/1) + Calcium pantothenate (10 mg/1) + Pyridoxal Phosphate (12.5 mg/1) + Riboflavin (1.7 mg/1) + Thiamine mononitrate (1.5 mg/1) + Vitamin C (120 mg/1) Capsule, gelatin coated Oral Pure Source, Llc 2015-08-11 Not applicable US - Categories
- Benzoquinones
- Cardiac Therapy
- Cardiovascular System
- Coenzymes
- Diet, Food, and Nutrition
- Electron Transport Chain Complex Proteins
- Enzymes and Coenzymes
- Food
- Food and Beverages
- Growth Substances
- Micronutrients
- Other Nutritional Agents
- P-glycoprotein/ABCB1 Substrates
- Physiological Phenomena
- Quinones
- Vitamins
- UNII
- EJ27X76M46
- CAS number
- 303-98-0
- Weight
- Average: 863.3435
Monoisotopic: 862.683911368 - Chemical Formula
- C59H90O4
- InChI Key
- ACTIUHUUMQJHFO-UPTCCGCDSA-N
- InChI
- InChI=1S/C59H90O4/c1-44(2)24-15-25-45(3)26-16-27-46(4)28-17-29-47(5)30-18-31-48(6)32-19-33-49(7)34-20-35-50(8)36-21-37-51(9)38-22-39-52(10)40-23-41-53(11)42-43-55-54(12)56(60)58(62-13)59(63-14)57(55)61/h24,26,28,30,32,34,36,38,40,42H,15-23,25,27,29,31,33,35,37,39,41,43H2,1-14H3/b45-26+,46-28+,47-30+,48-32+,49-34+,50-36+,51-38+,52-40+,53-42+
- IUPAC Name
- 2-[(2E,6E,10E,14E,18E,22E,26E,30E,34E)-3,7,11,15,19,23,27,31,35,39-decamethyltetraconta-2,6,10,14,18,22,26,30,34,38-decaen-1-yl]-5,6-dimethoxy-3-methylcyclohexa-2,5-diene-1,4-dione
- SMILES
- COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O
Pharmacology
- Indication
The diet supplements containing ubidecarenone are indicated, as stated in the product label, to assist individuals with cardiovascular complaints including congestive heart failure and systolic hypertension. In the product, ubidecarenone is used to increase the cardiac input as well as for the prevention of several other diseases like Parkinson, fibromyalgia, migraine, periodontal disease and diabetes, based on preclinical studies.[9] It is important to highlight that these products are not FDA approved and it is recommended to use under discretion.
- Structured Indications
- Not Available
- Pharmacodynamics
Ubidecarenon has roles in many prysiological process including sulfide oxidation, regulation of mitochondrial permeability transition pore and translocation of protons and calcium ions accross biological membranes. Studies have shown its benefitial effect in treating cancer, statin myopathy, congestive heart failure and hypertension.[2]
- Mechanism of action
Ubidecarenone is an essential cofactor in the mitochondrial electron transport chain. Its functions are the acceptance of electrons from the complex I and II and this activity is vital for the production of ATP. It acts as a mobile redox agent shuttling electrons and protons in the electron transport chain.[5] Ubidecarenone also presents antioxidant activity in mitochondria and cellular membranes, protecting against peroxidation of lipid membranes as well as inhibiting oxidation of LDL-cholesterol.[10]
Target Actions Organism ANADH dehydrogenase [ubiquinone] flavoprotein 3, mitochondrial cofactorHuman ASuccinate dehydrogenase [ubiquinone] flavoprotein subunit, mitochondrial cofactorHuman - Absorption
Ubidecarenone is absorbed from the small intestine into the lymphatics and then it can enter the blood. The hydrophobicity and large molecular weight limit its absorption making it very poor and variable depending on the food intake and the number of lipids presented in the food. The absorption is lower in the presence of an empty stomach and greater in presence of high lipid food diet. The daily dosage of ubidecarenone presents the reach of maximal serum concentration by reaching a plateau after three weeks.[10] The pharmacokinetic properties may vary between different brands but studies have reported an AUC of 11.51 mcg h/ml and a Cmax of 0.32 mcg/ml at a time of 7.9 h.[3]
- Volume of distribution
Ubidecarenone is distributed to the various tissues of the body and it is able to enter the brain.[10] In preclinical studies with intravenous administration of ubidecarenone, it is reported a volume of distribution of 20.4 L/kg which reflects its ability to penetrate extensively into organs and tissues.[4] AS a general rule, tissues with high-energy requirements or metabolic activity tend to presents higher amounts of ubidecarenone, these organs can be heart, kidney, liver and muscle.[5]
- Protein binding
In the blood, ubidecarenone is split into the various lipoprotein particles including LDL and VLDL.[10] The plasma concentration of ubidecarenone is highly dependent on the presence of plasma lipoproteins and about 95% of the administered form is found in the reduced form.[5]
- Metabolism
Studies indicate that there is no saturation process during the metabolism of ubidecarenone. It is metabolized in all tissues by the phosphorylation in the cells and transportation to the kidneys for further excretion by the urine.[11] After exerting its action, ubidecarenone is reduced and forms hydroquinone which is capable of recycling and regenerates other antioxidants such as tocopherol and ascorbate. The later metabolism of hydroquinone generates the formation of Q acid I and Q acid II in free and conjugated forms.[5]
- Route of elimination
The main elimination route of ubidecarenone is through the bile. After its oral administration, over 60% of the dose is excreted in the feces in the form of unchanged ubidecarenone and a small fraction of the metabolites.[10, 5] In the urine, ubidecarenone is bound to saposin B protein and represents only 8.3% of the total administered dose.[5]
- Half life
The pharmacokinetic properties may vary between different brands but studies have reported a half-life of ubidecarenone of 21.7 h.[3]
- Clearance
In preclinical studies with intravenous administration of ubidecarenone, it is reported a total clearance of 1.18 ml h/kg which was indicative of a prolonged elimination.[4]
- Toxicity
There have not been reports of adverse events of diet supplementation with ubidecarenone.[6] The normal side effects reported in humans are related to the gastrointestinal tract.[5]
- Affected organisms
- Humans and other mammals
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
Drug Interaction Drug group 2,4-thiazolidinedione The therapeutic efficacy of 2,4-thiazolidinedione can be increased when used in combination with Ubidecarenone. Investigational Acarbose The therapeutic efficacy of Acarbose can be increased when used in combination with Ubidecarenone. Approved, Investigational Acetohexamide The therapeutic efficacy of Acetohexamide can be increased when used in combination with Ubidecarenone. Approved, Investigational, Withdrawn AICA ribonucleotide The therapeutic efficacy of AICA ribonucleotide can be increased when used in combination with Ubidecarenone. Experimental, Investigational Allicin The therapeutic efficacy of Allicin can be increased when used in combination with Ubidecarenone. Investigational Alogliptin The therapeutic efficacy of Alogliptin can be increased when used in combination with Ubidecarenone. Approved Apalutamide The serum concentration of Ubidecarenone can be decreased when it is combined with Apalutamide. Approved, Investigational Balaglitazone The therapeutic efficacy of Balaglitazone can be increased when used in combination with Ubidecarenone. Investigational Bempedoic acid The therapeutic efficacy of Bempedoic acid can be increased when used in combination with Ubidecarenone. Investigational Buformin The therapeutic efficacy of Buformin can be increased when used in combination with Ubidecarenone. Investigational, Withdrawn Canagliflozin The therapeutic efficacy of Canagliflozin can be increased when used in combination with Ubidecarenone. Approved Carbutamide The therapeutic efficacy of Carbutamide can be increased when used in combination with Ubidecarenone. Experimental Castanospermine The therapeutic efficacy of Castanospermine can be increased when used in combination with Ubidecarenone. Experimental Chlorpropamide The therapeutic efficacy of Chlorpropamide can be increased when used in combination with Ubidecarenone. Approved, Investigational Ciglitazone The therapeutic efficacy of Ciglitazone can be increased when used in combination with Ubidecarenone. Experimental Deoxyspergualin The therapeutic efficacy of Deoxyspergualin can be increased when used in combination with Ubidecarenone. Investigational Doxorubicin The risk or severity of adverse effects can be decreased when Ubidecarenone is combined with Doxorubicin. Approved, Investigational Dulaglutide The therapeutic efficacy of Dulaglutide can be increased when used in combination with Ubidecarenone. Approved, Investigational Empagliflozin The therapeutic efficacy of Empagliflozin can be increased when used in combination with Ubidecarenone. Approved Exenatide The therapeutic efficacy of Exenatide can be increased when used in combination with Ubidecarenone. Approved, Investigational Glibornuride The therapeutic efficacy of Glibornuride can be increased when used in combination with Ubidecarenone. Investigational, Withdrawn Gliclazide The therapeutic efficacy of Gliclazide can be increased when used in combination with Ubidecarenone. Approved Glimepiride The therapeutic efficacy of Glimepiride can be increased when used in combination with Ubidecarenone. Approved Glipizide The therapeutic efficacy of Glipizide can be increased when used in combination with Ubidecarenone. Approved, Investigational Gliquidone The therapeutic efficacy of Gliquidone can be increased when used in combination with Ubidecarenone. Approved, Investigational Glyburide The therapeutic efficacy of Glyburide can be increased when used in combination with Ubidecarenone. Approved Gusperimus The therapeutic efficacy of Gusperimus can be increased when used in combination with Ubidecarenone. Investigational Insulin Aspart The therapeutic efficacy of Insulin Aspart can be increased when used in combination with Ubidecarenone. Approved Insulin Detemir The therapeutic efficacy of Insulin Detemir can be increased when used in combination with Ubidecarenone. Approved Insulin Glargine The therapeutic efficacy of Insulin Glargine can be increased when used in combination with Ubidecarenone. Approved Insulin Glulisine The therapeutic efficacy of Insulin Glulisine can be increased when used in combination with Ubidecarenone. Approved Insulin Human The therapeutic efficacy of Insulin Human can be increased when used in combination with Ubidecarenone. Approved, Investigational Insulin Lispro The therapeutic efficacy of Insulin Lispro can be increased when used in combination with Ubidecarenone. Approved Insulin Pork The therapeutic efficacy of Insulin Pork can be increased when used in combination with Ubidecarenone. Approved Isavuconazole The serum concentration of Ubidecarenone can be increased when it is combined with Isavuconazole. Approved, Investigational Linagliptin The therapeutic efficacy of Linagliptin can be increased when used in combination with Ubidecarenone. Approved Liraglutide The therapeutic efficacy of Liraglutide can be increased when used in combination with Ubidecarenone. Approved Lovastatin The serum concentration of Ubidecarenone can be decreased when it is combined with Lovastatin. Approved, Investigational Lumacaftor The serum concentration of Ubidecarenone can be decreased when it is combined with Lumacaftor. Approved Metformin The therapeutic efficacy of Metformin can be increased when used in combination with Ubidecarenone. Approved Miglitol The therapeutic efficacy of Miglitol can be increased when used in combination with Ubidecarenone. Approved Miglustat The therapeutic efficacy of Miglustat can be increased when used in combination with Ubidecarenone. Approved Mitiglinide The therapeutic efficacy of Mitiglinide can be increased when used in combination with Ubidecarenone. Approved, Investigational Nateglinide The therapeutic efficacy of Nateglinide can be increased when used in combination with Ubidecarenone. Approved, Investigational Phenformin The therapeutic efficacy of Phenformin can be increased when used in combination with Ubidecarenone. Approved, Investigational, Withdrawn Pioglitazone The therapeutic efficacy of Pioglitazone can be increased when used in combination with Ubidecarenone. Approved, Investigational Piperine The serum concentration of Ubidecarenone can be increased when it is combined with Piperine. Investigational Pitolisant The serum concentration of Ubidecarenone can be decreased when it is combined with Pitolisant. Approved, Investigational Pramlintide The therapeutic efficacy of Pramlintide can be increased when used in combination with Ubidecarenone. Approved, Investigational Pravastatin The serum concentration of Ubidecarenone can be decreased when it is combined with Pravastatin. Approved Propranolol The therapeutic efficacy of Ubidecarenone can be decreased when used in combination with Propranolol. Approved, Investigational Ranolazine The serum concentration of Ubidecarenone can be increased when it is combined with Ranolazine. Approved, Investigational Repaglinide The therapeutic efficacy of Repaglinide can be increased when used in combination with Ubidecarenone. Approved, Investigational Rosiglitazone The therapeutic efficacy of Rosiglitazone can be increased when used in combination with Ubidecarenone. Approved, Investigational Saxagliptin The therapeutic efficacy of Saxagliptin can be increased when used in combination with Ubidecarenone. Approved Simvastatin The serum concentration of Ubidecarenone can be decreased when it is combined with Simvastatin. Approved Sitagliptin The therapeutic efficacy of Sitagliptin can be increased when used in combination with Ubidecarenone. Approved, Investigational Sotagliflozin The therapeutic efficacy of Sotagliflozin can be increased when used in combination with Ubidecarenone. Investigational Sulodexide The therapeutic efficacy of Sulodexide can be increased when used in combination with Ubidecarenone. Approved, Investigational Tolazamide The therapeutic efficacy of Tolazamide can be increased when used in combination with Ubidecarenone. Approved, Investigational Tolbutamide The therapeutic efficacy of Tolbutamide can be increased when used in combination with Ubidecarenone. Approved, Investigational Troglitazone The therapeutic efficacy of Troglitazone can be increased when used in combination with Ubidecarenone. Investigational, Withdrawn Vemurafenib The serum concentration of Ubidecarenone can be increased when it is combined with Vemurafenib. Approved Vildagliptin The therapeutic efficacy of Vildagliptin can be increased when used in combination with Ubidecarenone. Approved, Investigational Voglibose The therapeutic efficacy of Voglibose can be increased when used in combination with Ubidecarenone. Approved, Investigational Warfarin The therapeutic efficacy of Warfarin can be decreased when used in combination with Ubidecarenone. Approved - Food Interactions
- Not Available
References
- General References
- Ernster L, Dallner G: Biochemical, physiological and medical aspects of ubiquinone function. Biochim Biophys Acta. 1995 May 24;1271(1):195-204. [PubMed:7599208]
- Xue R, Yang J, Wu J, Meng Q, Hao J: Coenzyme Q10 inhibits the activation of pancreatic stellate cells through PI3K/AKT/mTOR signaling pathway. Oncotarget. 2017 Sep 23;8(54):92300-92311. doi: 10.18632/oncotarget.21247. eCollection 2017 Nov 3. [PubMed:29190916]
- Kang EY, Choi JW, Gwak HS, Chun IK: Comparison of bioavailability of two ubidecarenone products in healthy Korean volunteers. Int J Clin Pharmacol Ther. 2009 Mar;47(3):207-14. [PubMed:19281730]
- Kalenikova EI, Gorodetskaya EA, Medvedev OS: Pharmacokinetics of coenzyme q10. Bull Exp Biol Med. 2008 Sep;146(3):313-6. [PubMed:19240848]
- Bhagavan HN, Chopra RK: Coenzyme Q10: absorption, tissue uptake, metabolism and pharmacokinetics. Free Radic Res. 2006 May;40(5):445-53. doi: 10.1080/10715760600617843. [PubMed:16551570]
- Shults CW, Oakes D, Kieburtz K, Beal MF, Haas R, Plumb S, Juncos JL, Nutt J, Shoulson I, Carter J, Kompoliti K, Perlmutter JS, Reich S, Stern M, Watts RL, Kurlan R, Molho E, Harrison M, Lew M: Effects of coenzyme Q10 in early Parkinson disease: evidence of slowing of the functional decline. Arch Neurol. 2002 Oct;59(10):1541-50. [PubMed:12374491]
- FDA Reports [Link]
- Pubmedhealth [Link]
- Diet supplement label [Link]
- Coenzyme Q [Link]
- Journal of Health Science [Link]
- External Links
- Human Metabolome Database
- HMDB0001072
- KEGG Drug
- D01065
- KEGG Compound
- C11378
- PubChem Compound
- 5281915
- PubChem Substance
- 310265165
- ChemSpider
- 4445197
- ChEBI
- 46245
- ChEMBL
- CHEMBL454801
- HET
- U10
- Wikipedia
- Coenzyme_Q10
- ATC Codes
- C01EB09 — Ubidecarenone
- AHFS Codes
- 88:30.00* — Other Nutritional Agents
- PDB Entries
- 1aig / 1aij / 1bcc / 1ds8 / 1dv3 / 1dv6 / 1e14 / 1e6d / 1f6n / 1fnp … show 93 more
- MSDS
- Download (92.4 KB)
Clinical Trials
- Clinical Trials
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage forms
Form Route Strength Capsule Oral 50 mg Capsule Oral 100 mg Solution Oral Tablet Oral 10 mg Capsule Oral 50.0 mg Capsule Oral 12 mg Tablet Oral 100 mg Capsule Oral 60 mg Capsule Oral 80 mg Capsule Oral 15 mg Capsule Oral 30 mg Powder Oral Capsule Oral 10 mg Tablet Oral Capsule Oral Tablet Oral 60 mg Capsule Oral 25 mg Capsule Oral 20 mg Capsule, gelatin coated Oral - Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Solid
- Experimental Properties
Property Value Source melting point (°C) 50-52ºC MSDS water solubility Sparingly soluble MSDS logP 10 Lucangioli S. and Tripodi V., Der Pharmacia Sinica, (2012), 3 (4):406-407 - Predicted Properties
Property Value Source Water Solubility 0.000193 mg/mL ALOGPS logP 9.94 ALOGPS logP 17.16 ChemAxon logS -6.6 ALOGPS pKa (Strongest Basic) -4.7 ChemAxon Physiological Charge 0 ChemAxon Hydrogen Acceptor Count 4 ChemAxon Hydrogen Donor Count 0 ChemAxon Polar Surface Area 52.6 Å2 ChemAxon Rotatable Bond Count 31 ChemAxon Refractivity 286.61 m3·mol-1 ChemAxon Polarizability 112.38 Å3 ChemAxon Number of Rings 1 ChemAxon Bioavailability 0 ChemAxon Rule of Five No ChemAxon Ghose Filter No ChemAxon Veber's Rule No ChemAxon MDDR-like Rule No ChemAxon - Predicted ADMET features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Taxonomy
- Description
- This compound belongs to the class of organic compounds known as ubiquinones. These are coenzyme Q derivatives containing a 5, 6-dimethoxy-3-methyl(1,4-benzoquinone) moiety to which an isoprenyl group is attached at ring position 2(or 6).
- Kingdom
- Organic compounds
- Super Class
- Lipids and lipid-like molecules
- Class
- Prenol lipids
- Sub Class
- Quinone and hydroquinone lipids
- Direct Parent
- Ubiquinones
- Alternative Parents
- Polyterpenoids / Polyprenylbenzoquinones / P-benzoquinones / Vinylogous esters / Organic oxides / Hydrocarbon derivatives
- Substituents
- Polyterpenoid / Polyprenylbenzoquinone / Ubiquinone skeleton / Quinone / P-benzoquinone / Vinylogous ester / Cyclic ketone / Ketone / Organic oxygen compound / Organic oxide
- Molecular Framework
- Aliphatic homomonocyclic compounds
- External Descriptors
- ubiquinones (CHEBI:46245) / ubiquinones, Coenzymes (C11378) / Ubiquinones (LMPR02010001)
Targets
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Yes
- Actions
- Cofactor
- General Function
- Poly(a) rna binding
- Specific Function
- Accessory subunit of the mitochondrial membrane respiratory chain NADH dehydrogenase (Complex I), that is believed not to be involved in catalysis. Complex I functions in the transfer of electrons ...
- Gene Name
- NDUFV3
- Uniprot ID
- P56181
- Uniprot Name
- NADH dehydrogenase [ubiquinone] flavoprotein 3, mitochondrial
- Molecular Weight
- 11940.435 Da
References
- Bhagavan HN, Chopra RK: Coenzyme Q10: absorption, tissue uptake, metabolism and pharmacokinetics. Free Radic Res. 2006 May;40(5):445-53. doi: 10.1080/10715760600617843. [PubMed:16551570]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Yes
- Actions
- Cofactor
- General Function
- Succinate dehydrogenase activity
- Specific Function
- Flavoprotein (FP) subunit of succinate dehydrogenase (SDH) that is involved in complex II of the mitochondrial electron transport chain and is responsible for transferring electrons from succinate ...
- Gene Name
- SDHA
- Uniprot ID
- P31040
- Uniprot Name
- Succinate dehydrogenase [ubiquinone] flavoprotein subunit, mitochondrial
- Molecular Weight
- 72690.975 Da
References
- Bhagavan HN, Chopra RK: Coenzyme Q10: absorption, tissue uptake, metabolism and pharmacokinetics. Free Radic Res. 2006 May;40(5):445-53. doi: 10.1080/10715760600617843. [PubMed:16551570]
Enzymes
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- No
- Actions
- Substrate
- General Function
- Nadph binding
- Specific Function
- Transmembrane glycoprotein that is the rate-limiting enzyme in cholesterol biosynthesis as well as in the biosynthesis of nonsterol isoprenoids that are essential for normal cell function including...
- Gene Name
- HMGCR
- Uniprot ID
- P04035
- Uniprot Name
- 3-hydroxy-3-methylglutaryl-coenzyme A reductase
- Molecular Weight
- 97475.155 Da
References
- Coenzyme Q [Link]
Carriers
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- No
- Actions
- Substrate
- General Function
- Virus receptor activity
- Specific Function
- Binds LDL, the major cholesterol-carrying lipoprotein of plasma, and transports it into cells by endocytosis. In order to be internalized, the receptor-ligand complexes must first cluster into clat...
- Gene Name
- LDLR
- Uniprot ID
- P01130
- Uniprot Name
- Low-density lipoprotein receptor
- Molecular Weight
- 95375.105 Da
References
- Coenzyme Q [Link]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- No
- Actions
- Substrate
- General Function
- Very-low-density lipoprotein particle receptor activity
- Specific Function
- Binds VLDL and transports it into cells by endocytosis. In order to be internalized, the receptor-ligand complexes must first cluster into clathrin-coated pits. Binding to Reelin induces tyrosine p...
- Gene Name
- VLDLR
- Uniprot ID
- P98155
- Uniprot Name
- Very low-density lipoprotein receptor
- Molecular Weight
- 96097.45 Da
References
- Coenzyme Q [Link]
Transporters
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- No
- Actions
- Substrate
- General Function
- Xenobiotic-transporting atpase activity
- Specific Function
- Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
- Gene Name
- ABCB1
- Uniprot ID
- P08183
- Uniprot Name
- Multidrug resistance protein 1
- Molecular Weight
- 141477.255 Da
References
- Journal of Health Science [Link]
Drug created on October 28, 2015 09:41 / Updated on April 23, 2018 23:13